28 / 33
Page 82
conferenceseries
.com
Volume 7, Issue 6 (Suppl)
J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460
Dementia 2017
October 16-18, 2017
ALZHEIMER’S DISEASE & DEMENTIA
October 16-18, 2017 | Rome, Italy
9
th
International Conference on
J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl)
DOI: 10.4172/2161-0460-C1-034
Predictive molecular diagnosis of Alzheimer’s Dementia: Towards new clinical models for preventive
treatment
Jens Wiltfang
Georg August University Göttingen, Germany
T
here is an unmet need for first preventive, that is disease-modifying, treatments of Alzheimer´s dementia (AD). However,
preventive treatment calls for predictive diagnosis since novel preventive treatment options can only be offered if patients
are identified during preclinical stages of the incipient AD. Per definition, a preclinical stage can not be detected by clinical
tools and accordingly, patients at high risk for later AD have to be identified by biomarker guided predictive diagnostics. The
presentation will demonstrate that patients with preclinical AD can meanwhile be identified within the clinically heterogenous
cohort of Mild Cognitive Impairment (MCI) with positive and negative predictive values of at least 90% by a multiparameter
biomarker approach relying on CSF dementia biomarkers, MRI volumetry and/or F18-Amyloid-PET. In view of a prevalence
of approximately 20% of preclinical AD within the MCI risk cohort the latter predictive values are clinically significant.
Morevover, it will be critically discussed in how far first blood-based assays may support the identification of preclinical AD.
Finally, the presentation will exemplify that novel diagnostic targets may indicate promising novel therapeutic targets.
Jens.Wiltfang@med.uni-goettingen.de